Fed. Circ. Rules Myriad Can Patent Breast Cancer Genes
A New York federal judge had previously ruled that the DNA molecules isolated by Myriad fell within the realm of nonpatentable “products of nature” because the individual genes are not markedly different from the same DNA sequence found naturally.
But the appeals court said Myriad's BRCA1...
To view the full article, register now.